Critical FDA Meeting Looms for IO Biotech’s Survival

IO Biotech faces a pivotal moment in its corporate history as financial pressures mount and regulatory challenges intensify. The biotechnology firm’s future hangs in the balance following mixed clinical trial results and dwindling cash reserves that have created a race against time.

The company’s financial position reveals significant strain, with recent figures painting a concerning picture:

• Cash reserves have diminished to just $31 million
• Current funding is projected to last only through the first quarter of 2026
• Third-quarter operations resulted in a net loss of $8.4 million
• September saw workforce reductions totaling 50 percent

Although aggressive restructuring measures have reduced operating expenses from Read more...